CLINICAL_TRIALS
trial_result
· 2019-05-17
Clinical Trial Update: Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) [Phase 2]
Summary
Phase 2 trial update of Brentuximab Vedotin in high-risk CD30+ lymphoma after allogeneic stem cell transplantation.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-17